NASDAQ-listed pharmaceutical company Teligent opened a laboratory with an investment volume of almost a million euros in Tallinn last week. The laboratory will initially focus on analytical chemistry, but has set its sights also on conducting product development for various generic drugs.
Right now, the lab focused its work on analytical chemistry, including developing and checking various methods of analysis, Teligent Eesti manager Anneli Simm told BNS on Friday.
“These are necessary to test the chemical and physical properties of the company’s U.S. and Canadian pharmaceutical products. In the longer term, Teligent is planning to conduct product development for various generic medicines in Tallinn,” Simm said.
The laboratory, with a total floor area of almost 300 square meters, employs a workforce of five now and will hire another five specialists with a background in medicine and chemistry once working at full capacity.
The facility also includes administrative space for quality assurance and supply chain employees who oversee the company’s third-party contract manufacturing activities around the world.
The New Jersey-based specialty generic pharmaceutical company established its operation in Estonia in 2015, where it has managed logistics and supply relations between third-party suppliers and the U.S. and Canadian markets.
Editor: Editor: Dario Cavegn